Summit Therapeutics Inc. annual report, FY2021

Summit Therapeutics Inc. — 2021 Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2021. Summit is a development-stage biopharmaceutical company with no approved products or product-sales revenue. Its lead candidate, ridinilazole, is being developed for Clostridioides difficile infection (CDI); SMT-738 was in preclinical development for drug-resistant Enterobacteriaceae infections.

Financial results and liquidity

• Revenue came from the Eurofarma licensing arrangement and milestone payments, not product sales. Other operating income chiefly comprised $15.2 million of U.K. R&D tax credits and $4.6 million of BARDA funding.
• At year-end, cash was $71.8 million; current assets were $97.3 million and current liabilities $25.6 million. Assets also included $15.7 million in R&D tax-credit receivables and $1.5 million in accounts receivable.
• Net cash from financing activities was $77.9 million, including $74.8 million net proceeds from the May 2021 rights offering. The $55 million CEO-related note was repaid from offering proceeds. The filing reports no outstanding borrowing balance at December 31, 2021; on March 10, 2022, the CEO provided a new unsecured $25 million note.
• Lease obligations totaled $2.9 million. Other contractual commitments were estimated at $17.0 million, mostly due within one year; most related contracts were cancellable.
• Management said available resources, including the subsequent $25 million note, were expected to fund operating costs and working capital into the second half of 2023. The company nevertheless expects continuing losses and needs additional capital. No meaningful product gross margin is reported because there are no product sales.

Material changes versus 2020

• Net loss widened by $35.9 million, primarily as operating expenses rose $35.6 million. R&D expense increased $32.1 million, particularly from Phase III ridinilazole clinical and manufacturing activity and higher compensation and stock-based compensation.
• Revenue increased $0.9 million, reflecting the second Eurofarma enrollment milestone earned in 2021. Other operating income rose $1.7 million: higher R&D tax credits and CARB-X income were partly offset by lower BARDA income.
• Operating cash use increased $24.5 million. Stock-based compensation rose to $12.8 million from $1.8 million, including expense associated with modification of performance-based options.
• Summit combined the two blinded Phase III ridinilazole trials into one study. The FDA did not agree with the company’s proposed change to the primary endpoint. The December 2021 topline result did not meet the primary endpoint for superiority.

Outlook, commentary and principal risks

• Ridinilazole produced a numerically higher sustained clinical response rate than vancomycin but failed to demonstrate the prespecified superiority required by the primary endpoint. Summit reported substantially less CDI recurrence with ridinilazole (nominal p=0.0002) and said it was well tolerated; it planned further data and microbiome analyses and was evaluating next steps, including potential partnerships. These topline findings do not establish regulatory approval or commercial prospects.
• Summit’s stated strategic emphasis is microbiome-focused therapeutics in anti-infectives and oncology, including potential collaborations and acquisitions. SMT-738 remained preclinical; CARB-X support included up to $4.1 million initially and a possible additional $3.7 million subject to milestones.
• BARDA had provided $56.5 million of its $62.4 million committed funding by year-end. Further support depended on BARDA exercising a final option at its discretion, subject to milestones. BARDA funding may also carry government rights and compliance requirements.
• Principal risks include the failed Phase III primary endpoint, uncertainty over ridinilazole’s path and partnership prospects, dependence on additional financing, continuing losses, clinical and regulatory uncertainty, reliance on third-party manufacturers and trial operators, competition and potential dilution. COVID-19 had slowed enrollment at some sites and created operational and supply-chain uncertainty.
• The financial statements received an unqualified audit opinion. The auditor highlighted the need for additional financing and identified accrued and prepaid R&D costs as a critical audit matter because they depend on estimates of study progress and costs incurred.

Important facts for investors to verify

1. Review the complete Ri-CoDIFy results, including the primary endpoint analysis, recurrence data, safety, study design and FDA feedback on the endpoint change.
2. Track management’s decision on ridinilazole development or partnering, and any subsequent FDA engagement or regulatory plan.
3. Assess the cash runway assumptions, actual operating cash burn, availability of future financing, and terms and repayment trigger for the $25 million CEO note.
4. Confirm BARDA’s remaining option status and future funding, and monitor whether expected U.K. R&D tax-credit receivables are collected.
5. Evaluate SMT-738’s preclinical progress, CARB-X milestone conditions, and the timing and funding required for IND-enabling work.
6. Consider governance and dilution exposure: the CEO beneficially owned approximately 70% of the company at year-end, and stock options and warrants represented potential future share issuance.